As the center of life sciences innovation increasingly shifts to China, companies must be ready for a more complex international arbitration landscape.
In this panel discussion with experienced practitioners in life sciences arbitrations, we will explore how their experience on intellectual property misappropriation, diversion to China, limited discovery, difficult collections, and rulings that attempted to cross geographic boundaries can inform companies’ licensing, contracting, and strategies to prepare for disputes.
We will examine how China’s growing role in clinical trials (particularly in oncology and biologics, along with expanding PD-1/PD-L1 development and broader clinical trial capabilities) raises new considerations for anticipating and understanding arbitration needs in an increasingly China-centered innovation environment.
Speakers:
Preeti Bhagnani, Partner, White & Case
Joe Profaizer, Partner, Global Co-Head of International Arbitration, Linklaters
Peter Rankin, Vice President, Charles River Associates
Thomas Walsh, Partner, Freshfields
Moderator:
Tiago Duarte-Silva, Vice President, Charles River Associates
For more information on registration, click here.
